Surgical management of congenital maxillo-mandibular bony fusion (syngnathia): Technical insights from a three-case retrospective series.

J Craniomaxillofac SurgJun 24, 2026 (epub)
Case ReportPlastic SurgeryOtolaryngology (ENT)

Mohamed Mostafa Elshamaa, Mahmoud Fata, Sarah Arafat et al.

✦ AI-curated · Sources linked

Case in brief

Three cases of congenital syngnathia, characterized by maxillo-mandibular bony fusion, were reported. Patients presented with airway compromise and feeding difficulties, necessitating early surgical intervention. The surgical management effectively addressed these critical issues, improving the patients' ability to feed and breathe, thereby preventing potential life-threatening complications.

Diagnostic / clinical pearl

Congenital syngnathia can lead to severe airway and feeding challenges, making early surgical intervention crucial for patient survival and quality of life.

Source

PubMed · PMID 42341579

Published in J Craniomaxillofac Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.